Introduction: Ovarian torsion is an emergency condition that occurs when the adnexa undergoes complete or partial rotation. Following ovarian torsion, damage caused by ischemia/reperfusion can impact fertility and sex hormone secretion. Our study aims to investigate the role of safranal in preventing ovarian ischemia-reperfusion injury in rats. Methods: Animal subgroups included: Sham, ovarian torsion/detorsion (OT), ovarian torsion/detorsion with the treatment of Safranal (OTS 0.1, 0.5), and Safranal group (OS 0.1,0.5). Ovarian torsion was induced in the left ovary of rats for 2 hours. Treatment with Safranal in 0.1 and 0.5 mg/kg/IP doses was administered 30 minutes before the detorsion operation. 48 hours after detorsion, ovarian tissue was collected to evaluate the histopathological scores and apoptosis gene expression of Bcl-2, caspase 3, and Bax. Blood samples were collected to measure plasma estradiol levels and oxidative stress parameters. Results: Analyses demonstrated that ovarian follicular damage accompanied an increase in serum malondialdehyde (MDA) levels and the expression of Bcl2 and caspase-3 genes after ovarian torsion. Additionally, serum levels of glutathione peroxidase (GPx), estrogen, and superoxide dismutase (SOD) decreased in the OT group. However, treatment with Safranal 0.5 mg/kg was accompanied by an improvement in the histopathological score of the ovarian tissue and a reduction in apoptosis and oxidative stress. Conclusions: The administration of Safranal may be effective in anti-oxidative stress activity due to ovarian torsion in a rat model. Dose-dependent Safranal treatment can be considered a low-cost therapeutic option before ovarian detorsion in the gynecological clinic.